Myl stock price – mylan n.v. stock quote (u.s. nasdaq) – marketwatch gas tax


Mylan shares dropped 2% in premarket trade Wednesday after the company reported a first-quarter revenue miss and profit beat. Earnings for the latest quarter rose to $87.1 million, or 17 cents per share, from $66.4 million, or 12 cents per share in the year-earlier period. Adjusted earnings-per-share were 96 cents, above the FactSet consensus of 95 cents. Revenue declined to $2.68 billion from $2.72 billion, below the FactSet consensus of $2.73 billion. The latest results include a year-over-year decline in North America net sales, driven by a decrease in sales of branded products like the EpiPen, among other factors. Following reports of EpiPen shortages in Canada and the United Kingdom, an advocacy group said this week that the U.S. is facing a growing national shortage of EpiPens and other allergic reaction treatments, which the Food and Drug Administration denied. Mylan also affirmed its 2018 revenue guidance of $11.75 billion to $13.25 billion and its 2018 adjusted EPS guidance of $5.20 to $5.60. Mylan shares were inactive in Wednesday premarket trade. Shares have dropped nearly 10% over the last three months, compared with a 2% rise in the S&P 500 and a 0.7% rise in the Dow Jones Industrial Average .

Allergy advocacy group Food Allergy Research and Education says that the U.S. is facing a growing national shortage of EpiPens and other allergic reaction treatments called epinephrine auto-injectors. Individuals with food allergies have found it difficult to fill their prescriptions in as many as 14 states as of late April, the group said. The American Society of Health-System Pharmacists, a professional organization for pharmacists, also said that there was a shortage of Mylan’s EpiPen , with the EpiPen, EpiPen Jr. for children and the authorized generic version "on intermittent back order with regular releases," earlier this month. A rival product manufactured by Kaleo was still available, the group said. The Food and Drug Administration did not immediately return MarketWatch’s request for comment, but a spokesperson said in late April that it was not aware at that time of any shortage. A FDA spokesperson then called it a "spot shortage" in late April, according to the publication Allergic Living. The advocacy group FARE said it wrote to FDA Commissioner Scott Gottlieb on May 1 about its concerns, and said on Monday that it was calling on the FDA to declare the issue a national shortage. EpiPen shortages have been seen in Canada and the United Kingdom. FARE also questioned whether there was a connection between the supply issues and problems at a Pfizer unit that manufactures the EpiPen, and asked the FDA to push for other allergic reaction treatments from Teva and Adamis Pharmaceuticals Corp. , which got its Symjepi product approved last July, though the product has not been brought to market.

Mylan N.V.’s stock rallied 1.0% in morning trade Thursday, after the generic drugmaker was upgraded at Leerink Partners, which cited a more positive pipeline outlook. Analyst Ami Fadia raised her rating to outperform from market perform, while keeping the stock price target at $52. Fadia said her upgrade comes after she left Mylan’s investor day on Wednesday "incrementally more positive" on the pipeline, the diversified business model, and its ability to grow profit and sales over the next several years. "There are several near-term catalysts that we believe should drive upside to Mylan including regulatory approvals and launches of biosimilar Neulasta in the U.S. (June 4), Gx Advair in the U.S. (June 27), Gx Restasis (July 31), biosimilar Humira in EU (2H18), Revefenacin in the US (Nov. 13) and new product launches of biosimilar Herceptin in the U.S. (potentially late 2018), and insulin glargine in E.U. (2H18)," Fadia wrote in a note to clients. Mylan shares have tumbled 13.0% over the past three months, while the SPDR S&P Pharmaceuticals ETF has dropped 8.4% and the S&P 500 has slipped 4.4%.

Mylan N.V.’s stock ran up 3.8% in morning trade Tuesday, after Morgan Stanley analyst David Risinger turned bullish on the generic drug maker for the first time, citing greater confidence in growth prospects relative to peers and optimism over its drug pipeline. Risinger raised his rating to overweight, after being at equal weight since starting coverage three years ago, and raised the stock price target to $50 from $39. "Beyond its strong pipeline of new products, Mylan has opportunities to gain share relative to generic competitors which are facing challenges," Risinger wrote in a note to clients. He said the No. 1 market player Teva Pharmaceutical Industries Ltd. is in the process of restructuring and cutting its workforce, the No. 3 player Sandoz’s U.S oral generics unit is reportedly up for sale and the No. 8 player Apotex has faced leadership challenges. Mylan’s stock has rallied 16.7% over the past three months, while the SPDR S&P Pharmaceuticals ETF has tacked on 1.1% and the S&P 500 has gained 3.6%.